Statins Linked to Longer Lives in Nasopharyngeal Cancer Survivors — 7,872-Person Hong Kong Cohort
A Hong Kong registry cohort of 7,872 five-year NPC survivors: statin users showed higher 10/15/20-year survival (89.1 vs 71.8% at 10 y); HR 0.71 after immortal-time-bias adjustment. Association, not causation.
By Sanare Lab · October 13, 2026 · 2 min read
Key Takeaway
People who survived nasopharyngeal cancer (a head-and-neck cancer common in southern China) lived longer if they took statins — cholesterol-lowering pills — in a Hong Kong registry study of 7,872 survivors. This is observational: a strong association, not proof of cause.
The study followed 5-year survivors of non-metastatic nasopharyngeal cancer (NPC) diagnosed in 1997–2015: 2,439 statin users versus 5,433 non-users, balanced with inverse probability weighting (a statistical method that makes compared groups alike). The primary outcome was overall survival — the share still alive. At 10 years past the 5-year mark, 89.1% of statin users were alive versus 71.8% of non-users; at 20 years, 59.2% versus 42.4% (hazard ratio HR 0.46 — HR 1 means no difference, below 1 means fewer deaths).
Long-term statin users must, by definition, live long enough to keep taking them — a classic trap called immortal time bias. After adjusting for it, the association held at HR 0.71 (p<0.001 — statistically solid). Statin users also died less often from second cancers (HR 0.51), heart disease (HR 0.64), and lung disease (HR 0.64); use beyond 6 years showed the strongest link (HR 0.31). Newer-generation statins looked better (HR 0.66 and 0.41) — an exploratory finding the authors say needs validation.
Observational links can reflect healthier users rather than drug effects — only randomized trials can prove benefit. See our earlier statin-and-survival cohort and the Korean statin cohort; dosing questions: our dosing calculator.
In plain words
What happened: Researchers compared 7,872 Hong Kong residents who had survived 5 years after nasopharyngeal cancer — those taking statins (cholesterol pills) versus those not taking them.
Why it matters: Long-term survivors die earlier than their peers, partly from second cancers and heart disease. Statins are cheap and common, and might lower some of those risks.
How strong is the evidence: A large registry study, but observational — it shows association, not cause. After correcting a classic statistical bias the link stayed (29% lower death rate); only a randomized trial can prove benefit.
What it means for you: If you survived cancer, do not start statins on your own for this — they are prescription drugs with real side effects. Ask your doctor whether you have heart-health reasons for one.
References
- Effect of statins on the mortality of long-term survivors of nasopharyngeal carcinoma: a population-based study in endemic area (retrospective cohort — observational registry data). The Lancet Regional Health – Western Pacific. 2026 Oct. doi:10.1016/j.lanwpc.2026.101993. PMID: 42861289.
Medical Disclaimer
This article is for informational purposes only and is not medical advice. The study is observational and cannot prove cause and effect. Never start, stop or change any medication without consulting your doctor.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.